• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$224.91
+0 (0.00%)
Get New MyoKardia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYOK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYOK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for MyoKardia in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $224.91.

This chart shows the closing price for MYOK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in MyoKardia. This rating has held steady since October 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
6/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 10 hold ratings
  • 0 sell ratings
9/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/15/2020Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
10/6/2020CSFBReiterated RatingOutperform ➝ Neutral$225.00Low
10/6/2020CowenDowngradeOutperform ➝ Market Perform$145.00 ➝ $225.00Low
10/6/2020WedbushDowngradeOutperform ➝ Neutral$127.00 ➝ $225.00Low
10/6/2020Credit Suisse GroupReiterated RatingOutperform ➝ Neutral$225.00Low
10/6/2020Wells Fargo & CompanyInitiated CoverageOverweight ➝ Equal Weight$133.00 ➝ $225.00Low
10/6/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$121.00 ➝ $225.00Low
10/6/2020CitigroupDowngradeBuy ➝ Neutral$125.00 ➝ $225.00Low
10/6/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$148.00 ➝ $225.00Low
10/5/2020Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
10/5/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
10/5/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal WeightLow
8/31/2020BMO Capital MarketsReiterated RatingBuy$148.00High
8/5/2020Credit Suisse GroupReiterated RatingBuy$136.00Low
7/15/2020Morgan StanleyBoost TargetOverweight$117.00 ➝ $121.00Medium
5/20/2020Cantor FitzgeraldBoost TargetOverweight$95.00 ➝ $188.00Medium
5/14/2020BMO Capital MarketsBoost TargetOutperform$90.00 ➝ $148.00High
5/12/2020CitigroupBoost TargetBuy$87.00 ➝ $125.00Medium
5/12/2020WedbushBoost Target$90.00 ➝ $127.00High
5/11/2020CowenBoost TargetOutperform$104.00 ➝ $145.00High
5/11/2020Credit Suisse GroupBoost TargetOutperform$82.00 ➝ $136.00High
5/7/2020Morgan StanleyBoost TargetOverweight$83.00 ➝ $87.00Medium
4/15/2020Morgan StanleyBoost TargetOverweight$76.00 ➝ $83.00Medium
3/31/2020Cantor FitzgeraldReiterated RatingBuy$95.00High
3/26/2020BMO Capital MarketsReiterated RatingBuy$90.00Low
3/5/2020CowenReiterated RatingBuy$104.00Low
2/28/2020Morgan StanleyBoost TargetOverweight$75.00 ➝ $76.00High
2/11/2020Credit Suisse GroupBoost TargetOutperform ➝ Positive$77.00 ➝ $82.00High
2/7/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
1/27/2020GuggenheimReiterated RatingBuy$86.00Low
1/17/2020Wells Fargo & CompanyBoost TargetOverweight ➝ Positive$82.00 ➝ $96.00Medium
12/20/2019CitigroupBoost TargetBuy$70.00 ➝ $87.00Medium
12/17/2019Morgan StanleyBoost TargetOverweight$70.00 ➝ $75.00Low
11/11/2019CowenReiterated RatingBuy$73.00Low
10/28/2019Maxim GroupReiterated RatingAverageHigh
10/22/2019CowenReiterated RatingBuy$73.00Low
9/19/2019GuggenheimInitiated CoverageBuyHigh
8/8/2019WedbushBoost TargetOutperform$87.00 ➝ $90.00Low
8/8/2019CowenReiterated RatingBuy$73.00High
7/15/2019Morgan StanleySet TargetBuy$71.00High
5/20/2019JPMorgan Chase & Co.Boost TargetOverweight$75.00 ➝ $85.00Medium
5/9/2019Cantor FitzgeraldReiterated RatingBuy$90.00Medium
3/5/2019BMO Capital MarketsBoost TargetOutperform$90.00Medium
3/4/2019Cantor FitzgeraldReiterated RatingBuy$90.00High
2/22/2019BMO Capital MarketsInitiated CoverageOutperform$85.00Low
1/4/2019Credit Suisse GroupLower TargetOutperform ➝ Outperform$73.00 ➝ $71.00High
1/3/2019CitigroupLower TargetBuy ➝ Buy$90.00 ➝ $70.00Medium
11/9/2018WedbushReiterated RatingOutperform$77.00High
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$90.00High
9/28/2018CitigroupInitiated CoverageBuy ➝ Buy$90.00Medium
9/10/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$72.00High
8/10/2018JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$80.00 ➝ $81.00Medium
8/9/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$70.00 ➝ $73.00High
8/9/2018WedbushReiterated RatingOutperform ➝ Outperform$77.00 ➝ $64.00Medium
7/10/2018Bank of AmericaInitiated CoverageBuy$71.00High
5/22/2018CowenReiterated RatingBuy$73.00High
4/13/2018Wells Fargo & CompanyReiterated RatingOutperform$70.00Medium
3/9/2018CowenReiterated RatingBuy$56.00Low
3/9/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$65.00 ➝ $83.00High
3/9/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$60.00 ➝ $68.00High
3/9/2018WedbushBoost TargetOutperform$51.00 ➝ $69.00High
1/18/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$60.00Low
12/12/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$54.00Medium
(Data available from 12/1/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/5/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/4/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/2/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/2/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/1/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
MyoKardia logo
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $224.91
Low: $224.91
High: $224.91

50 Day Range

MA: $224.61
Low: $222.81
High: $224.91

52 Week Range

Now: $224.91
Low: $42.65
High: $225.00

Volume

N/A

Average Volume

752,969 shs

Market Capitalization

$11.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84

Frequently Asked Questions

What sell-side analysts currently cover shares of MyoKardia?

The following Wall Street analysts have issued research reports on MyoKardia in the last twelve months:
View the latest analyst ratings for MYOK.

What is the current price target for MyoKardia?

0 Wall Street analysts have set twelve-month price targets for MyoKardia in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for MyoKardia in the next year.
View the latest price targets for MYOK.

What is the current consensus analyst rating for MyoKardia?

MyoKardia currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MYOK.

What other companies compete with MyoKardia?

How do I contact MyoKardia's investor relations team?

MyoKardia's physical mailing address is 1000 SIERRA POINT PARKWAY, BRISBANE CA, 94005. The biotechnology company's listed phone number is 650-741-0900 and its investor relations email address is [email protected] The official website for MyoKardia is www.myokardia.com. Learn More about contacing MyoKardia investor relations.